Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Time to Sell?

Posted by Amy Steele on Feb 8th, 2026

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report)’s share price gapped down prior to trading on Friday . The stock had previously closed at $68.6950, but opened at $64.0750. Zealand Pharma A/S shares last traded at $64.0750, with a volume of 153 shares traded.

Analysts Set New Price Targets

ZLDPF has been the topic of a number of analyst reports. BTIG Research upgraded Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Five investment analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Zealand Pharma A/S presently has a consensus rating of “Buy”.

Get Our Latest Research Report on Zealand Pharma A/S

Zealand Pharma A/S Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10. The stock has a market capitalization of $4.55 billion, a PE ratio of 4.61 and a beta of 0.72. The stock’s 50 day moving average is $71.41 and its two-hundred day moving average is $70.10.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.21. The business had revenue of $7.76 million during the quarter, compared to analysts’ expectations of $4.54 million. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%. On average, equities analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.